KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Receivables (2016 - 2025)

Historic Change in Receivables for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $156.0 million.

  • AbbVie's Change in Receivables rose 14534.88% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 89559.75%. This contributed to the annual value of -$207.0 million for FY2024, which is 21363.64% down from last year.
  • Per AbbVie's latest filing, its Change in Receivables stood at $156.0 million for Q3 2025, which was up 14534.88% from $17.0 million recorded in Q2 2025.
  • AbbVie's Change in Receivables' 5-year high stood at $1.5 billion during Q1 2025, with a 5-year trough of -$590.0 million in Q3 2021.
  • Its 5-year average for Change in Receivables is $218.7 million, with a median of $156.0 million in 2025.
  • Examining YoY changes over the last 5 years, AbbVie's Change in Receivables showed a top increase of 26000.0% in 2024 and a maximum decrease of 1710000.0% in 2024.
  • Quarter analysis of 5 years shows AbbVie's Change in Receivables stood at $749.0 million in 2021, then tumbled by 44.46% to $416.0 million in 2022, then plummeted by 181.49% to -$339.0 million in 2023, then decreased by 14.16% to -$387.0 million in 2024, then soared by 140.31% to $156.0 million in 2025.
  • Its Change in Receivables stands at $156.0 million for Q3 2025, versus $17.0 million for Q2 2025 and $1.5 billion for Q1 2025.